2.93
price up icon3.17%   0.09
after-market After Hours: 2.90 -0.03 -1.02%
loading
Telomir Pharmaceuticals Inc stock is traded at $2.93, with a volume of 178.84K. It is up +3.17% in the last 24 hours and down -27.65% over the past month. Telomir Pharmaceuticals Inc is a pioneering preclinical-stage pharmaceutical company which leads the advancement of age-reversal science. The Company is focused on developing Telomir-1, a novel small molecule designed to lengthen and protect telomeres-the protective DNA end caps of chromosomes that are crucial to cellular aging. As humans and animals age, telomeres naturally shorten, with metal reactivity accelerating this process, increasing the risk of degenerative and age-related diseases. By addressing the underlying causes of aging at the cellular level, Telomir aims to tackle the root of these conditions rather than simply treating their symptoms. Telomir is conducting ongoing preclinical research into Progeria, diabetes, cancer, Alzheimer's disease, osteoarthritis, and others.
See More
Previous Close:
$2.84
Open:
$2.8
24h Volume:
178.84K
Relative Volume:
1.22
Market Cap:
$87.20M
Revenue:
-
Net Income/Loss:
$-13.08M
P/E Ratio:
-6.635
EPS:
-0.4416
Net Cash Flow:
-
1W Performance:
-25.82%
1M Performance:
-27.65%
6M Performance:
-46.04%
1Y Performance:
-59.92%
1-Day Range:
Value
$2.61
$3.08
1-Week Range:
Value
$2.61
$4.005
52-Week Range:
Value
$2.61
$9.39

Telomir Pharmaceuticals Inc Stock (TELO) Company Profile

Name
Name
Telomir Pharmaceuticals Inc
Name
Phone
786-396-6723
Name
Address
100 SE 2ND ST, MIAMI
Name
Employee
0
Name
Twitter
Name
Next Earnings Date
2024-11-11
Name
Latest SEC Filings
Name
TELO's Discussions on Twitter

Compare TELO with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
TELO
Telomir Pharmaceuticals Inc
2.93 87.20M 0 -13.08M 0 -0.4416
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
474.62 121.88B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
573.45 62.69B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
555.11 33.86B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
235.74 30.51B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
238.51 25.69B 3.81B -644.79M -669.77M -6.24

Telomir Pharmaceuticals Inc Stock (TELO) Upgrades & Downgrades

Date Action Analyst Rating Change
Feb-21-25 Initiated Rodman & Renshaw Buy

Telomir Pharmaceuticals Inc Stock (TELO) Latest News

pulisher
Apr 02, 2025

Charles Schwab Investment Management Inc. Boosts Position in Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) - Defense World

Apr 02, 2025
pulisher
Apr 01, 2025

TELO stock touches 52-week low at $3.1 amid market challenges By Investing.com - Investing.com South Africa

Apr 01, 2025
pulisher
Apr 01, 2025

TELO stock touches 52-week low at $3.1 amid market challenges - Investing.com India

Apr 01, 2025
pulisher
Apr 01, 2025

Virtu Financial LLC Acquires Shares of 14,959 Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) - Defense World

Apr 01, 2025
pulisher
Mar 29, 2025

Bank of New York Mellon Corp Increases Stock Position in Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) - Defense World

Mar 29, 2025
pulisher
Mar 25, 2025

Analyzing Telomir Pharmaceuticals (TELO) & The Competition - Defense World

Mar 25, 2025
pulisher
Mar 23, 2025

Telomir Pharmaceuticals Announces Significant Anti-Cancer Effects in Prostate Cancer Animal Model Using Highly Aggressive Human Prostate Cancer Cells - Bluefield Daily Telegraph

Mar 23, 2025
pulisher
Mar 21, 2025

Telomir Pharmaceuticals announces anti-cancer effects in prostate cancer animal model - MSN

Mar 21, 2025
pulisher
Mar 19, 2025

SWK Holdings Announces Monetization of Royalty Portfolio - Waco Tribune-Herald

Mar 19, 2025
pulisher
Mar 19, 2025

Telomir-1 shows promise in cancer and chemotherapy study By Investing.com - Investing.com South Africa

Mar 19, 2025
pulisher
Mar 19, 2025

Telomir Pharmaceuticals Says Telomir-1 Reduces Tumor Size in Prostate Cancer Animal Model - MarketScreener

Mar 19, 2025
pulisher
Mar 19, 2025

Telomir-1 shows promise in cancer and chemotherapy study - Investing.com

Mar 19, 2025
pulisher
Mar 19, 2025

Telomir Pharmaceuticals reports breakthrough in prostate cancer treatment By Investing.com - Investing.com South Africa

Mar 19, 2025
pulisher
Mar 19, 2025

Telomir Pharmaceuticals reports breakthrough in prostate cancer treatment - Investing.com India

Mar 19, 2025
pulisher
Mar 19, 2025

Breakthrough: New Cancer Drug Cuts Prostate Tumors by Half While Reducing Chemo Toxicity - StockTitan

Mar 19, 2025
pulisher
Mar 19, 2025

Telomir Pharmaceuticals Lead Drug Candidate Inhibits Tumor Growth In Aggressive Prostate Cancer Cells, Animal Study Shows - Benzinga

Mar 19, 2025
pulisher
Mar 12, 2025

Rhumbline Advisers Boosts Position in Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) - Defense World

Mar 12, 2025
pulisher
Mar 04, 2025

Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) Short Interest Up 34.4% in February - Defense World

Mar 04, 2025
pulisher
Feb 26, 2025

Telomir-1 shows promise in reversing cell aging By Investing.com - Investing.com South Africa

Feb 26, 2025
pulisher
Feb 26, 2025

Telomir-1 shows promise in reversing cell aging - Investing.com India

Feb 26, 2025
pulisher
Feb 26, 2025

Telomir Pharmaceuticals Announces Breakthrough: Telomir-1 Reverses Calcium Dysregulation, the Hidden Driver of Aging and Disease, in Multiple Human Cell Lines - Eagle-Tribune

Feb 26, 2025
pulisher
Feb 26, 2025

Could This Anti-Aging Compound Revolutionize Treatment for Alzheimer's and Macular Degeneration? - StockTitan

Feb 26, 2025
pulisher
Feb 25, 2025

Telomir Pharmaceuticals announces Telomir-1 reverses calcium dysregulation in multiple human cell lines - MSN

Feb 25, 2025
pulisher
Feb 25, 2025

Telomir Pharmaceuticals reports key preclinical success By Investing.com - Investing.com South Africa

Feb 25, 2025
pulisher
Feb 25, 2025

Telomir Pharmaceuticals reports key preclinical success - Investing.com India

Feb 25, 2025
pulisher
Feb 25, 2025

Telomir Pharmaceuticals achieves breakthrough in silver ion stabilization - MSN

Feb 25, 2025
pulisher
Feb 24, 2025

Telomir Pharmaceuticals (NASDAQ:TELO) Research Coverage Started at Rodman & Renshaw - Defense World

Feb 24, 2025
pulisher
Feb 23, 2025

Telomir-1 exhibited strong ROS reduction properties, hold potential for AMD treatment - Ophthalmology Times

Feb 23, 2025
pulisher
Feb 21, 2025

Telomir reports stabilization of silver forms for medical use By Investing.com - Investing.com Nigeria

Feb 21, 2025
pulisher
Feb 21, 2025

Telomir Pharmaceuticals Says Telomir-1 Compound Stabilizes Silver for Advanced Medical Applications - Marketscreener.com

Feb 21, 2025
pulisher
Feb 21, 2025

Telomir reports stabilization of silver forms for medical use - Investing.com

Feb 21, 2025
pulisher
Feb 21, 2025

Telomir Pharmaceuticals Achieves Breakthrough in Silver Ion Stabilization, Unlocking a Multi-Billion-Dollar Medical Market - Weatherford Democrat

Feb 21, 2025
pulisher
Feb 20, 2025

Telomir Pharmaceuticals announces silver ion breakthrough - Investing.com

Feb 20, 2025
pulisher
Feb 20, 2025

Telomir Pharmaceuticals Seeks To Tap Multi-Billion-Dollar Market With Breakthrough In Silver Ion Stabilization For Antibacterial Treatment, Tissue Regeneration - Benzinga

Feb 20, 2025
pulisher
Feb 18, 2025

TELO Again Announces Breakthrough Results - MSN

Feb 18, 2025
pulisher
Feb 18, 2025

Telomir Pharmaceuticals Announces Significant Reduction of Oxidative Stress in Human Retinal Cell Lines, Advancing Potential Treatment for Age-Related Macular Degeneration (AMD) - Milton Daily Standard

Feb 18, 2025
pulisher
Feb 10, 2025

What is Zacks Small Cap's Estimate for TELO Q1 Earnings? - MarketBeat

Feb 10, 2025
pulisher
Feb 08, 2025

Telomir Pharmaceuticals (NASDAQ:TELO) Announces Earnings Results, Misses Estimates By $0.05 EPS - MarketBeat

Feb 08, 2025
pulisher
Feb 08, 2025

What is Zacks Small Cap’s Estimate for TELO Q1 Earnings? - Defense World

Feb 08, 2025
pulisher
Feb 04, 2025

Telomir Pharmaceuticals Inc. (TELO) reports earnings - Quartz

Feb 04, 2025
pulisher
Feb 03, 2025

TELO Treatment Amazes in Preclinical Trial - MSN

Feb 03, 2025
pulisher
Feb 03, 2025

Will These 5 Big Drug Stocks Surpass Q4 Earnings Forecasts? - Barchart

Feb 03, 2025
pulisher
Feb 02, 2025

Telomir Pharmaceuticals Announces Major Breakthrough in Reversing Oxidative Stress, Unlocking Potential for Treating Age-Related Diseases and Viruses Like Bird Flu - Barchart

Feb 02, 2025
pulisher
Jan 31, 2025

Thrombotic Thrombocytopenic Purpura Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | Global Blood Therapeutics, Sanofi, Carelon Research, Archemix Corp., Eisai Inc - Barchart

Jan 31, 2025

Telomir Pharmaceuticals Inc Stock (TELO) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$60.58
price down icon 3.01%
$69.18
price down icon 5.66%
$17.36
price down icon 8.20%
$31.11
price down icon 2.14%
$88.05
price down icon 4.30%
biotechnology ONC
$238.51
price down icon 9.76%
Cap:     |  Volume (24h):